Evidence map›Paper›PMID 31674314›Full record

ArticleThe Lancet. Oncology2019

What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.

Jeremie Calais, Francesco Ceci, Matthias Eiber, Thomas A Hope, Michael S Hofman, Christoph Rischpler, Tore Bach-Gansmo, Wolfgang P Fendler, Johannes Czernin

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. AnCurrent radiopharmaceuticals · 2024
    Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jeremie CalaisAhmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, University of California Los Angeles, CA 900095-7370, USA; Institute of Urologic Oncology, University of California Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, CA, USA. Electronic address: jcalais@mednet.ucla.edu.
Francesco CeciAhmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, University of California Los Angeles, CA 900095-7370, USA; Nuclear Medicine, Department of Medical Sciences, University of Turin, Italy.
Matthias EiberAhmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, University of California Los Angeles, CA 900095-7370, USA; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA.
Michael S HofmanMolecular Imaging and Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Christoph RischplerDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Tore Bach-GansmoDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Wolfgang P FendlerAhmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, University of California Los Angeles, CA 900095-7370, USA; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, University of California Los Angeles, CA 900095-7370, USA; Institute of Urologic Oncology, University of California Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Positron Emission Tomography Computed TomographyGallium IsotopesGallium RadioisotopesHumansMaleMembrane GlycoproteinsOrganometallic CompoundsProspective StudiesProstatectomyProstatic Neoplasmsgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesMembrane GlycoproteinsOrganometallic Compounds

Identifiers

PMID31674314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.